The first participants have been dosed in VESPER-6 and SOLIS-1, part of 20+ study starts planned across Pfizer's obesity pipeline in 2026.
Learn more about our pipeline:
pfizer.com/pipeline
We dosed the first participants in VESPER-6, the latest Phase 3 trial of our lead investigational medicine in obesity and started a Phase 2b study testing it in combination with an investigational amylin analog.